drugset / Trial / NCT07270042
Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection
RandomizedSequentialDouble-blindTreatment
Summary
This clinical trial seeks to investigate a promising new approach to enhance the effectiveness and duration of Botulinum Toxin A (BTX-A) for the treatment of hyperactive masseter muscles. By investigating the role of oral zinc supplementation, this study could provide a cost-effective, sustainable solution for patients suffering from both aesthetic concerns and functional limitations associated with MMH and bruxism. The findings of this study will expand the clinical applications of BTX-A, offering longer-lasting relief and reducing the need for frequent injections, which could revolutionize the management of MMH in clinical practice.
Timeline
- Start
- 2025-12-01
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 25 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 30 iu | Intramuscular |
| Subject | Zinc gluconate | Small molecule | 50 mg | Oral |